AI-Powered Solutions for Small Molecule Drug Discovery

Dr. Bin Chen received Ph.D. from the University of Michigan, Ann Arbor and then carried out postdoctoral research at the Massachusetts Institute of Technology, with nearly 20 years of experience in pharmaceutical industry. Dr. Chen worked for Bristol-Meyers Squibb for 10 years, then joined WuXi AppTec and other biotechnology companies, during which he participated and led more than ten new drug discovery projects. In May 2021, Bin joined XtalPi as the head of Med.Chem. and has been spearheading our internal and external medchem efforts. Today in the webinar Bin will bring you an update about using our AI-driven revolutionary platform to overcome challenging problems in SMDD. 

Xtalpi's cutting-edge platform integrates artificial intelligence and automated synthesis to offer revolutionary strategies for addressing current small molecule drug discovery (SMDD) challenges through a "Design smarter, make faster" approach. In the webinar, you will get an exclusive, in-depth look at two of our most advanced SMDD platforms:

•   ID4Inno - Generative AI (ID4Idea) and quantum physics-based computation (ID4Gibbs) for exploring chemical space and precise property prediction

•   ChemArt - Transforming novel ideas into reality with automation platforms that offer swift deliveries with quality resultsThis comprehensive approach encompasses enhancing chemical spaces in novel compound design, mitigating time-intensive synthesis and purification processes, and accelerating DMTA cycles for efficient R&D.